However, in the present study, ACE inhibitors/ARBs (53%), beta-blockers (38%), and MRAs (26%) were used insufficiently at discharge, particularly in patients with HFrEF and sarcopenia (55%, 38%, and 34%, respectively). Here, ACE is linked to sarcopenia.